Systematic development of bombesin/gastrin-releasing peptide antagonists
- PMID: 1389686
Systematic development of bombesin/gastrin-releasing peptide antagonists
Abstract
Several families of very potent bombesin (Bn) receptor antagonist analogues have recently been developed and their biological potencies evaluated in a number of in vitro systems including guinea pig and rat pancreatic acini and Swiss 3T3 cells. These studies showed that analogues can exhibit diverse properties ranging from full antagonists, partial agonists, or full agonists depending on the assay system and animal species employed. We have developed two classes of more potent, shorter chain antagonists based on [psi CH2NH(13-14)]Bn(6-14) and desMet14Bn(6-13)NH2 structures. [D-Phe6 psi Leu13-Leu14] Bn(6-14)NH2 was a potent antagonist (Ki 6nM) in Swiss 3T3 cells and guinea pig acini but exhibited 10% partial agonist activity and lower binding affinity (Ki 60 nM) in rat acini. The partial agonism could be eliminated by using p-Cl-Phe or D-Phe at the C-terminus and partially eliminated using D-4-Cl-Phe in position 6. With the antagonist [D-Phe6]Bn(6-13)NH2 (Ki 96 nM), alkyl substituents on the amide group increased affinity 25-fold with the propylamide being the most potent peptide (Ki 4 nM) in 3T3 cells or guinea pig acini. It did, however, have high 40% partial agonist activity in rat acini. Alkyl esters or hydrazide derivatives were, in contrast, pure antagonists in all systems tested with [D-Phe6]Bn(6-13)OMe having the highest affinity in all systems and also excellent in vivo properties. All of the potent antagonists examined had little affinity for neuromedin B--preferring bombesin receptors, which had entirely new ligand structure-activity relationships.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.Mol Pharmacol. 1995 Apr;47(4):871-81. Mol Pharmacol. 1995. PMID: 7723750
-
A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects.Cell Growth Differ. 1992 Feb;3(2):111-8. Cell Growth Differ. 1992. PMID: 1323998
-
Discovery of high affinity bombesin receptor subtype 3 agonists.Mol Pharmacol. 1996 Nov;50(5):1355-63. Mol Pharmacol. 1996. PMID: 8913368
-
Progress in the development of potent bombesin receptor antagonists.Trends Pharmacol Sci. 1991 Jan;12(1):13-9. doi: 10.1016/0165-6147(91)90483-9. Trends Pharmacol Sci. 1991. PMID: 1706545 Review.
-
Bombesin receptor antagonists: different classes and cellular basis of action.Recent Results Cancer Res. 1993;129:87-113. doi: 10.1007/978-3-642-84956-5_8. Recent Results Cancer Res. 1993. PMID: 8394597 Review. No abstract available.
Cited by
-
Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.Bioconjug Chem. 2008 Oct;19(10):2040-8. doi: 10.1021/bc800290c. Epub 2008 Sep 23. Bioconjug Chem. 2008. PMID: 18808168 Free PMC article.
-
GRP-induced up-regulation of Hsp72 promotes CD16+/94+ natural killer cell binding to colon cancer cells causing tumor cell cytolysis.Clin Exp Metastasis. 2008;25(4):451-63. doi: 10.1007/s10585-008-9151-9. Epub 2008 Mar 19. Clin Exp Metastasis. 2008. PMID: 18350254
-
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.Pharmacol Rev. 2008 Mar;60(1):1-42. doi: 10.1124/pr.107.07108. Epub 2007 Nov 30. Pharmacol Rev. 2008. PMID: 18055507 Free PMC article. Review.
-
Mechanisms of bombesin on growth of gastrinoma (PT) in vivo.Dig Dis Sci. 1996 Nov;41(11):2180-6. doi: 10.1007/BF02071398. Dig Dis Sci. 1996. PMID: 8943970
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical